Cervical cancer vaccine inventor to target herpes

Cervical cancer vaccine inventor to target herpes

Cervical cancer vaccine inventor to target herpes
We hypothesized that the use of replication-incompetent HSV-1 lacking all IE/ genes except ICP0 could be convenient tools for the preparation of whole tumor vaccines because they might trigger apoptosis in tumor cells while upregulating danger signals, thereby producing strongly immunogenic whole tumor antigen for the preparation of DC tumor vaccines. This technology utilizes specific peptides which bind to CD4, CD8 or other proteins on the surface of T cells (T cell binding ligand (TCBL)), macrophage and dendritic cells (immune cell binding ligand (ICBL)) to promote the immunogenicity of an epitope, activate T cell and other protective responses, and direct the immune response to either a Th1 or a Th2 type of response. MGH1, G207) have been demonstrated to possess oncolytic effects as well as potent anticancer vaccination effects without compromising safety. Low immunogenic colon 26 cells were used for transfection and inoculation into syngeneic BALB/c mice. Admedus said further details in the results would be released once the analysis had been completed. 70% respectively). T-cell epitope analysis revealed that the mutated peptide GARC-1(77-85) (AALLNKLYA) but not the wild-type peptide (AALLDKLYA), was recognized by GCL-1.

Australia’s cervical cancer vaccine program, which provides free immunisation to school girls and boys in their first year of high school, is expected to reduce cervical cancer rates by up to 80 per cent. In conclusion, gene therapy with IL-18 and HSV-TK plasmid vector driven by the hTERT promoter may be useful for cancer vaccination.

You may also like